logo
Plus   Neg
Share
Email

Ligand Collaborates With GSK To Target Neurological Disorder; To Receive Up To $161 Mln Payment

Ligand Pharmaceuticals Inc.'s (LGND) subsidiary Icagen and GlaxoSmithKline (GSK,GSK.L) have reached a global collaboration and license agreement leveraging Icagen's discovery technology to target neurological disorder.

As per the terms of deal, Ligand will receive an upfront payment of $7 million. Ligand could receive additional development, regulatory and commercialization milestone payments, conditional on meeting those milestones, of up to $154.5 million.

Ligand will receive tiered royalties on net sales of any drug from the collaboration that is commercialized by GSK.

Ligand will be responsible for most preclinical activities up to lead optimization, with Ligand and GSK collaborating to identify candidates for entry into IND-enabling studies.

GSK has the exclusive option to license any identified inhibitors and will be responsible for the further development and commercialization of any drug candidates identified through the collaboration.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
AstraZeneca's one batch of Covid vaccine has been suspended by Austrian health authorities following reports of a death and an illness after receiving vaccination, reports said. The issues were reported in the district clinic of Zwettl in Lower Austria province. The Federal Office for Safety in Health Care in the country said the remaining stocks of the affected AstraZeneca/Oxford Covid-19 vaccine DuPont (DD) announced Monday that it has agreed to acquire Laird Performance Materials from with private equity firm Advent International for $2.3 billion. The company will use existing cash balances for the acquisition. The transaction is expected to close in the third quarter of 2021, subject to regulatory... Hu Products has recalled a single production lot of the Hu Chocolate Covered Hunks - Sour Goldenberries Product citing the possible presence of undeclared almonds, an allergen, the U.S. Food and Drug Administration said. The recall involves 4 oz. bags of the Hu Chocolate Covered Hunks - Sour Goldenberries with UPC code of 850180006510, Best By Date of 08/2021, and Lot Code of 202891.
Follow RTT